Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the women's environment, cancer and radiation epidemiology study

Journal of the National Cancer Institute

Volumn 100, Issue 1, 2008, Pages 32-40

  Bertelsen, Lisbeth ^a   Bernstein, Leslie ^b   Olsen, Jørgen H ^a   Mellemkjær, Lene ^a,n   Haile, Robert W ^b   Lynch, Charles F ^c   Malone, Kathleen E ^d   Anton Culver, H ^o   Christensen, Jane ^a   Langholz, Bryan ^b   Thomas, Duncan C ^b   Begg, C B ^f   Capanu, M ^f   Ejlertsen, Bent ^g   Stovall, Marilyn ^h   Boice, John D ^i,j   Shore, Roy E ^k   Bernstein, J L ^f   Bernstein, L ^m   Boice Jr , J D ^i,q   Børresen Dale, Anne Lise ^t   Concannon, Patrick ^t   Gatti, Richard A ^t   Haile, R W ^t   Langholz, B M ^m   Lynch, C F ^c   Malone, K E ^d   Olsen, J H ⁿ   Rosenstein, Barry ^t   Shore, R E ^p   Stovall, M ^h   Thomas, D C ^m   Thompson, W Douglas ^r   Liang, Xiaolin ^f   Wolitzer, Abigail ^f   Seminara, Daniela ^l   Donnelly Allen, Laura ^m   DeWall, Jeanne ^c   Epstein, Noemi ^d   Largent, Joan ^o   Smith, Susan ^h   Whittemore, Alice ^s   more..

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d USA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g University of Copenhagen   (Denmark)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^j VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^k NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l NATIONAL CANCER INSTITUTE   (United States)

^m UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁿ DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p NEW YORK UNIVERSITY   (United States)

^q VANDERBILT UNIVERSITY   (United States)

^r UNIVERSITY OF SOUTHERN MAINE   (United States)

^s STANFORD UNIVERSITY   (United States)

^t Vanderbilt University ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PROGESTERONE; TAMOXIFEN; TESTOSTERONE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CAF PROTOCOL 2; CMF REGIMEN; DRUG DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; BREAST TUMOR; CASE CONTROL STUDY; DRUG EFFECT; EPIDEMIOLOGY; MENOPAUSE; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARY; RISK ASSESSMENT; SECOND CANCER; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; CONFOUNDING FACTORS (EPIDEMIOLOGY); CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR MODULATORS; FEMALE; FLUOROURACIL; HUMANS; MENOPAUSE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, SECOND PRIMARY; OVARY; RADIOTHERAPY, ADJUVANT; RESEARCH DESIGN; RISK ASSESSMENT; TAMOXIFEN; TREATMENT OUTCOME;

EID: 38049156672     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm267     Document Type: Article

References (31)

1. Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999;8:855-861.
2. The Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
3. Annex - Figures 1-14 and separate Appendices to each of Tables 1-4. http://www.ctsu.ox.ac.uk/~ebctcg/systemic2000/annex.htm#Appendix% 20to%20Table%201. Accessed October 11, 2007.
4. Bernstein JL, Thompson WD, Risch N, Holford TR. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol. 1992;136:925-936.
5. Broet P, de la Rochefordiere A, Scholl SM, et al. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol. 1995;13:1578-1583.
6. Horn PL, Thompson WD. Risk of contralateral breast cancer. Associations with histologic, clinical, and therapeutic factors. Cancer. 1988;62:412-424.
7. Schaapveld M, Visser O, Louwman WJ, et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat. 2007 [Epub ahead of print].
8. Cook LS, Weiss NS, Schwartz SM, et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst. 1995;87:1359-1364.
9. Gajalakshmi CK, Shanta V, Hakama M. Risk factors for contralateral breast cancer in Chennai (Madras), India. Int J Epidemiol. 1998;27:743-750.
10. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006;24:5769-5779.
11. Dutertre M, Smith CL. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther. 2000;295:431-437.
12. Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst. 2003;95:1467-1476.
13. Bernstein JL, Langholz B, Haile RW, et al. Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study. Breast Cancer Res. 2004;6:R199-R214.
14. Langholz B, Borgan Ø. Counter-matching: a stratified nested case-control sampling method. Biometrika 1995;82:69-79.
15. World Health Organization. Obesity: preventing and managing the global epidemic. Geneva, Switzerland: WHO Technical Report Series; 2000.
16. Peto R. Five years of tamoxifen - or more? J Natl Cancer Inst. 1996;88:1791-1793.
17. Fowble B, Hanlon A, Freedman G, Nicolaou N, Anderson P. Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk. Int J Radiat Oncol Biol Phys. 2001;51:679-690.
18. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165:1267-1273.
19. Carmichael AR, Bates T. Obesity breast cancer: a review of the literature. Breast. 2004;13:85-92.
20. Li CI, Malone KE, Weiss NS, Daling JR. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst. 2001;93:1008-1013.
21. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88:1673-1682.
22. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96 months follow-up of the randomised IBIS-I trial. J Natl Cancer Inst. 2007;99:272-282.
23. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99:283-290.
24. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 2005;97:1652-1662.
25. Swain SM, Wilson JW, Mamounas EP, et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst. 2004;96:516-523.
26. Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol. 2005;23:4687-4694.
27. The Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
28. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst. 1996;88:1543-1549.
29. Kollias J, Man S, Marafie M, et al. Loss of heterozygosity in bilateral breast cancer. Breast Cancer Res Treat. 2000;64:241-251.
30. Imyanitov EN, Suspitsin EN, Grigoriev MY, et al. Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas. Int J Cancer. 2002;100:557-564.
31. Regitnig P, Ploner F, Maderbacher M, Lax SF. Bilateral carcinomas of the breast with local recurrence: analysis of genetic relationship of the tumors. Mod Pathol. 2004;17:597-602.